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Abstract 
Contamination of perfusion fluid (PF) could lead to serious infections in kidney transplant recipients. Preemptive ther-
apy (PE-T) in case of yeast contamination of PF is mandatory. The usefulness of PE-T in presence of bacteria remains 
unclear. In this study we evaluated the incidence of PF bacterial contamination and the impact of PE-T on clinical out-
come. Microbiological data of 290 PF and clinical data of the corresponding recipients collected in our hospital from 
January 2010 and December 2012 were analyzed. Recipients with bacterial contaminated PF (101) were divided in 3 
groups: group 1 (n = 52) PE-T treated bacteria resistant to perioperative antibiotic prophylaxis (PAP), group 2 (n = 28) 
bacteria sensitive to PAP, group 3 (n = 21) PE-T-untreated bacteria resistant to PAP. Incidence of positive PF was 34.8 %, 
50.4 % staphylococci, 9.9 % C. albicans. No significant differences in the rate of PF-related infections between the three 
groups were found. In conclusion, although PF contamination is frequent, the incidence of PF-related infections is 
very low. In addition, in this study PE-T did not help to reduce the rate of PF-related infection suggesting that a reson-
able reduction in the use of antibiotic terapy could be made. However, waiting for largest and prospective clinical 
trials to confirm our findings, a closely clinical and microbiologic monitoring of the recipient is highly recommended 
in case of PF contamination.
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Background
Infectious complications constitute the major cause of 
morbidity and mortality especially in the post-operative 
period in patients undergoing solid organ transplantation 
(Rubin 1993; Fishman and Rubin 1998). It is known that 
infections in transplanted patients might develop as con-
sequences of the immunosuppression-induced impair-
ment of the inflammatory response and of the exposure 
to hospital- and community-acquired pathogens such as 
viruses, bacteria and yeast. Moreover, infections can be 
transmitted from the donor through the contaminated 
graft (Grossi et al. 2009; Fisher et al. 2009). Beside donor 
infection, graft contamination can occur during several 
stages in the process of deceased donor transplantation 
including the contamination of the perfusion fluid (PF) 
used to perfuse the kidney following donor nephrectomy 
(Fisher et  al. 2009; Wakelin et  al. 2005). PF contamina-
tion can be due to exogenous pathogens derived from 
handling of the organs and the subsequently exposure to 
contaminants during the procurement process especially 
in the multi-organ procurement (Wakelin et  al. 2005). 
The incidence of PF contamination reported in litera-
ture ranges from 7 to 38.7 % and the pathogens isolated 
include Gram positive and negative bacteria and yeast 
(Anderson et al. 1978; Benoit et al. 1988; Mora et al. 1991; 
Sharma et al. 2005; Sauget et al. 2011; Veroux et al. 2010). 
It is known that contamination of PF could lead to seri-
ous infections such as mycotic arteritis and/or aneurysm 
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due to the destruction of the vascular structures in con-
sequence of the intense inflammatory response induced 
by bacteria or yeast infection (Fishman and Rubin 1998; 
Mai et al. 2006; Matignon et al. 2008; Albano et al. 2009; 
Gari-Tussaint et  al. 2004). Nevertheless, except in the 
case of PF contaminated by Candida sp where the gen-
eral consensus is to establish a preemptive therapy (PE-
T) (Matignon et al. 2008), it remains unclear whether an 
antibiotic PE-T might help to avoid infections in presence 
of PF contamination by bacteria.
In this retrospective study the rate of PF contamina-
tion, the incidence of PF-related infections in the kidney 
transplanted recipients and the impact of the antibiotic 
PE-T in presence of PF bacterial contamination on clini-
cal outcome were analyzed.
Methods
In this study, we carried out a retrospective analysis of 
290 PF samples and clinical data of patients receiving a 
kidney transplant from deceased multi-organ donors 
at our University hospital between January 2010 and 
December 2012. All recipients were followed up for at 
least 2 months post-transplantation. Recipient age, gen-
der, immunosuppressive therapy, post-transplant use of 
antibiotic, donor age and cold ischemia time were col-
lected. In addition, clinical and laboratory data such 
as body temperature, leukocyte count and C-reactive 
protein were collected daily for each recipient until dis-
charged from the hospital and, subsequently, weekly. 
A careful physical examination was undertaken every 
day and routinely urine cultures were performed every 
weeks after transplantation for the first 2  months and 
subsequently every 2  weeks until the third month after 
transplantation.
PF samples obtained from the bag containing the kid-
ney were collected before the back-table dissection of the 
graft prior to implantation. Each PF sample was inocu-
lated both in aerobic and anaerobic blood culture bottles 
(BacT/Alert®, BioMerieux) and subjected to microbio-
logical analysis.
All transplant recipients received prophylactic broad-
spectrum antibiotics (PAP) intravenously (iv) at surgery 
and at least for nine days after transplantation. From 
January 2010 to December 2011 a PE-T was adminis-
tered iv in the case of contaminated PF either by bac-
teria or yeast according to the antibiotic sensitivities. 
From January 2012, in order to reduce the potential 
acquirement of antimicrobial drug resistance and the 
development of multiresistant bacteria strains such as 
carbapenem-resistant Gram-negative pathogens, a PE-T 
was not administered in case of PF contaminated by bac-
teria. Nevertheless, the clinical and the laboratory mark-
ers of infection in the recipients receiving a graft with 
a contaminated PF were strictly monitored for at least 
20 days post-transplantation or as long as the patient was 
discharged from the hospital.
In presence of yeast strain isolation in the PF, antifungal 
PE-T with fluconazole was started promptly according 
to the antimicogram. In the case of yeast contamination 
of the PF, as demonstrated by a bacterioscopic analysis, 
an antifungal PE-T with caspofungin was established 
prior of the culture isolation of the yeast strain and sub-
sequently modified according to antifungal sensitivities. 
Caspofungin treatment was used as empiric therapy in 
the case of yeast contamination of PF for the follow rea-
sons: (i) some yeast are resistant to fluconazole (Candida 
glabrata and Candida kreusi); (ii) in this setting the risk 
to develop vessels infections, such as mycotic arteritis, 
is higher compared to urinary infection. Since caspo-
fungin reach high plasma concentration, this risk can be 
reduced. Recipients with yeast positive PF underwent 
blood, urine and drainage fluid cultures together with 
the daily screening of the inflammatory markers. In addi-
tion a Doppler ultrasound was performed at the time 
of diagnosis of contaminated PF by fungi to check vas-
cular anastomoses and repeated according to clinician’s 
assumption.
All recipients received co-trimoxazole for Pneu-
mocystic jiroveci prophylaxis starting from 10  days 
post-transplantation.
Statistical analysis was performed with SPSS (SPSS Inc. 
Chicago IL, vers. 20). Continuous variables are presented 
as mean ± standard deviation or as median [min–max], 
according to their distribution. The difference between 
groups was analyzed, respectively, with t test or Anova 
and Bonferroni and with Kruskal–Wallis test. Categorical 
variables are presented as fraction and Pearson’s χ2 or, for 
small samples, Fisher’s exact test was employed to com-
pare groups. Significance level for all tests was set at 0.05.
Results
The baseline characteristics of the 290 recipients and the 
transplant data are reported in Table  1. 101 out of 290 
samples of PF collected were contaminated with one or 
more organisms resulting in an overall incidence rate of 
34.8  % over the 3  years period. The organisms isolated 
were mainly staphylococci 51/101 (50.4 %), Staphylococ-
cus aureus was detected in 4 PFs (3.9  %). Pseudomonas 
aeruginosa and Candida albicans were isolated in 5 
(4.9 %) and in 10 (9.9 %) PF samples, respectively, Table 2. 
There were no significant differences in the immunosup-
pressive therapy between recipients who developed a PF-
related urinary infection and those who did not. None 
of the 10 recipients who received a graft with a con-
taminated PF by Candida albicans developed any signs 
related to fungal infection such as renal arteritis and/or 
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arterial aneurisms. Blood, urine and drainage fluid cul-
tures in these patients were negative. PAP was adminis-
tered to all transplanted recipients at surgery and for a 
mean duration of 12.5 ± 3.4 days post-transplantation as 
listed in Table 3. To test the impact of the antibiotic PE-T 
on the rate of infectious complications in transplanted 
patients receiving a graft with a positive PF for bacte-
ria we compared the following three groups of patients: 
group 1 (n  =  52) included patients with a pathogen in 
PF resistant to PAP that were subjected to PE-T, group 2 
(n = 28) included recipients with contaminated PF by an 
organism sensitive to the PAP and who did not received 
PE-T and, group 3 (n  =  21) included recipients with a 
pathogen in PF resistant to PAP who did not received 
PE-T. The mean duration of PE-T was 11.5 ± 4 days and 
the antibiotic regimens used are reported in Table 4. In 
the group 1, PE-T was started soon after the isolation of 
the pathogen in the perfusion fluid (7.1 ± 1.4 days post-
transplantation). 4/101 (3.9 %) of the transplant recipients 
who received a kidney with a contaminated PF developed 
a urinary infection, 1 (E. coli) in group 1 and 3 (2 E. coli, 
1 Staphylococcus epidermidis) in group 2, respectively. 
None of the patients in group 3 developed infections. No 
significant differences in the distribution of the organ-
ism isolated and in the rate of PF-related infections were 
found between the three groups. Noteworthy, among 
these bacteria, only one of the E. coli isolated in group 2, 
9 days after transplantation, displayed the same antibiotic 
sensitivity of the organism isolated in the PF suggesting 
that both samples could be contaminated by the same 
pathogen. The remaining 3 bacteria isolated in the urine 
did not seem to be the same strain found in PF on the 
basis of: (i) higher distance from transplantation (mean: 
19 days), and (ii) different antibiotic sensitivity. In order 
to evaluate whether some clinical and laboratory markers 
of inflammation could help to discriminate the recipients 
with contaminated PF who are at risk of developing PF-
related infections, we analyzed the following data: body 
temperature, leukocyte count, and C-reactive protein lev-
els at the time of reporting the positivity of the PF cul-
tures. No significant differences in such markers between 
the three groups were found, Table 5.
Discussion
Infections remain a serious complication of renal trans-
plantation. Pathogens could be transmitted to the recipi-
ent through a number of sources including the PF used to 
perfuse the kidney following donor nephrectomy (Fisher 
et al. 2009; Sharma et al. 2005; Sauget et al. 2011; Bucholz 
et al. 1985). At present, with the exception of fungi con-
tamination where there is a general consensus to treat 
Table 1 Baseline characteristics of the 290 patients
Continuous variables are expressed as mean ± SD
PF perfusion fluid, ID immunosuppression therapy
Contaminated PF 
(n = 101)
Non-contaminated 
PF (n = 189)
Donor
 Age, years 61.3 ± 13.9 59.7 ± 15.3
 Cold ischemia time, h 16.4 ± 3.8 15.8 ± 4.2
Recipient
 Age, years 55.7 ± 11.6 54.8 ± 11.5
 Sex (M/F) 69/32 129/60
Induction ID, No. (%)
 Thymoglobulin 7 (7) 3 (1)
 Basiliximab 100 (99) 186 (98)
 Rituximab 2 (2) 0
Maintenance ID, No. (%)
 Tacrolimus 88 (87.1) 142 (75.1)
 Cyclosporine 9 (8) 35 (18)
 Mycophenolate mofetil 77 (76.2) 133 (70.3)
 Everolimus 5 (5) 17 (9)
 Azathoprine 0 3 (1)
 Steroids 98 (97) 182 (96.3)
Table 2 Organisms isolated and  frequency of  their isola-
tion in the 101 contaminated PF
Other contaminants: Streptococcus mitis (2), gram positive cocci (4), Bacillus 
subtilis (1), Enterococcus raffinosus (1), Citrobacter freundi (2), Aeromonas 
hydrophilia (2), Corynebacterium (2), Serratia marcescensis (1), Morganella 
morganii (1), Klebsiella oxytoca (2), Enterobacter aerogenes (1)
PF perfusion fluid
Organism cultured Incidence, No. (%)
Staphylococci 51 (50.5)
 Staphylococcus aureus 4 (3.9)
 Staphylococcus epidermidis 22 (21.7)
 Staphylococcus hominis 14 (13.8)
 Staphylococcus haemolyticus 3 (2.9)
 Staphylococcus warneri 2 (1.9)
 Staphylococcus capitis 2 (1.9)
 Staphylococcus lugdunensis 1 (0.9)
 Staphylococcus simulans 1 (0.9)
 Staphylococcus cohnii 1 (0.9)
 Staphylococcus saprophyticus 1 (0.9)
Escherichia coli 17 (16.8)
Enterococcus faecalis 6 (5.9)
Pseudomonas aeruginosa 5 (4.9)
Acinetobacter baumani 1 (0.9)
Klebsiella pneumoniae 3 (2.9)
Candida albicans 10 (9.9)
Others contaminants 19 (18.8)
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the patient with an appropriate antifungal therapy based 
on PF-culture, it remains unclear whether a preemptive 
antibiotic therapy could lead to a reduction in the rate 
of infectious complications in case of PF contaminated 
by bacteria (Fisher et  al. 2009; Matignon et  al. 2008). 
In this retrospective study aimed to evaluate the rate 
of contaminated PF in our center and the impact of the 
preemptive therapy on the rate of PF-related infections, 
we found first of all a high percentage of contaminated 
PF together with an extremely low rate of infections PF-
related. As reported by other authors (Sharma et al. 2005; 
Sauget et al. 2011), also in our study we found a major-
ity of less pathogenic bacteria, such as staphylococci in 
positive PF. Nevertheless, a relevant number of bacteria 
considered highly pathogenic such as Pseudomonas aer-
uginosa and Gram-negative bacilli were found as well in 
our study. Consistently with the results of some recent 
reports, the high percentage of PF contaminated by skin 
contaminants such as coagulase-negative staphylococci 
may be due to i) the handling of the kidneys during the 
procurement process taking into account that all donors 
were multi-organ, and ii) the advances in microbiologi-
cal detection that became more sensitive during the last 
years (Wakelin et  al. 2005; Sauget et  al. 2011). Until 
December 2011 we adopted a preemptive antibiotic 
treatment based on PF-culture according to Sharma et al. 
(2005) that suggested a preemptive therapy in the case of 
lactose fermenting coliform or yeast and to Fisher et al. 
(2009) that extended the preemptive treatment also for 
less virulent organisms. Starting from January 2012 to 
December 2012, we did not adopt a preemptive therapy 
in case of PF contaminated by bacteria based on the fol-
lowing two issues. Firstly, the results of the analysis of 
the data regarding the infectious complications collected 
in our center during January 2010 and December 2011 
showed that only 1  % of the recipients who received a 
graft with a contaminated PF have developed an infec-
tion. Secondly, the increase of antibiotic resistant bac-
teria including carbapenem-resistant Gram-negative 
pathogens recently isolated in our hospital. Nevertheless, 
the inflammatory markers were screened daily until nor-
malization together with a careful physical examination 
performed every day in recipients receiving a kidney with 
a positive PF for bacteria.
We did not find any statistical differences in the rate of 
infections PF-related between patients who were treated 
with a preemptive therapy based on the results of PF 
Table 3 Perioperative antibiotic prophylaxis regimens 
administered in recipients receiving a graft with contami-
nated (n = 101) and non-contaminated PF (n = 189)
PF perfusion fluid
Antibiotic regimen Contaminated  
PF (n = 101)
Non-contaminated 
PF (n = 189)
No (%) No (%)
Co-amoxiclav 78 (77.3) 146 (77.2)
Fluoroquinolones 16 (15.8) 18 (9.5)
Other antibiotic regimens 7 (6.9) 25 (13.3)
Table 4 Summary of  the preemptive antibiotic regimens 
used
Antibiotic regimen No (%)
Fluoroquinolones 23 (44.2)
Fluconazole 9 (17.3)
Meropenem 6 (11.5)
Teicoplanin 5 (9.6)
Vancomycin 3 (5.7)
Caspofungin 2 (3.8)
Tazocin 1 (1.9)
Co-amoxiclav 1 (1.9)
Cephalosporin 1 (1.9)
Co-trimoxazole 1 (1.9)
Table 5 Clinical and laboratory markers of infections at the time of receiving the results of PF culture
Continuous variables are presented as mean ± SD or as median [min–max], according to their distribution. The difference between groups was analyzed, respectively, 
with t-test or Anova and Bonferroni and with Kruskal–Wallis test. Categorical variables are presented as fraction and Pearson’s χ2 or, for small samples, Fisher’s exact 
test was employed to compare groups. Significance level for all tests was set at 0.05
Group 1 patients with a pathogen in PF resistant to PAP that underwent PE-T, Group 2 recipients with contaminated PF by an organism sensitive to the PAP and 
who did not underwent PE-T, Group 3 recipients with a pathogen in PF resistant to PAP who did not underwent PE-T, PF perfusion fluid, PAP perioperative antibiotic 
prophylaxis, PE-T preemptive antibiotic therapy
Group 1 (n = 52) Group 2 (n = 28) Group 3 (n = 21)
Body temperature (°C) 36.2 ± 0.5 36 ± 0.5 36.1 ± 0.5 n.s.
C-reactive protein (mg/mL) 8.3 [1.5–120.8] 12.3 [0.9–43.5] 8.9 [2.5–57.00] n.s.
Leucocyte count (cells/μL) 7402 ± 2390 6359 ± 2311 7109 ± 1899 n.s.
Time post-transplant of diagnosis of PF contamination (days) 7.1 ± 1.4 6.6 ± 0.8 7.8 ± 1.9 n.s.
Duration of PE-T (days) 11.3 ± 3.9 – – –
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cultures and those untreated, irrespective of the isolated 
bacteria strain that were homogeneously distributed in 
the 3 groups. These findings are in agreement with recent 
reported data (Porco et  al. 2012). Moreover, there were 
no differences in the following clinical parameters: leuco-
cytes count, CRP and body temperature checked at the 
time of the results of the PF cultures between patients 
treated with preemptive therapy and those who were not.
Another important issue highlighted by this study is 
the reduction of the costs related to the administration 
of the preemptive therapy. In fact, analyzing data regard-
ing the percentage of bacteria contaminated PF found 
in our study, the type (see Table  4) and the duration of 
the preemptive therapy (11.5 ± 4 days) adopted, we cal-
culated that avoiding preemptive therapy in recipients 
who received a graft with a PF contaminated by bacteria 
could save about 5000 Euro per year. In addition, a rel-
evant number of studies demonstrated that antibiotic 
over-prescription leads to an increased rate of morbid-
ity and mortality from drug-resistance organisms such 
as extended-spectrum β-lactamases (ESBLs) and carbap-
enemase-producing bacteria which, in some cases, are 
capable of hydrolyzing almost all β-lactams including the 
carbapenems (Gutkind et al. 2013; Shigemura et al. 2011). 
Moreover, it should also be taken into account that a 
reduction of the use of fluoroquinolone is associated with 
a decrease in methicillin-resistant Staphylococcus aureus 
and a fluoroquinolone-resistant Pseudomonas aerugi-
nosa isolation rate (Lafaurie et  al. 2012). Thus, consist-
ently with the results of our study, we can speculate that 
the rate of drug-resistance organisms might be reduced 
proportionally by diminishing the use of a preemptive 
therapy in recipients who received a graft with a contam-
inated PF by bacteria.
Conclusions
At our knowledge this is the first study designed to 
evaluate the clinical impact of the preemptive therapy 
in the case of contaminated perfusion fluid. Never-
theless, we are aware of the limitations of this study. 
First of all this is a single center, retrospective study 
possibly subjected to treatment and observer biases; 
secondly we cannot completely exclude that the few 
urinary infections that developed after transplantation 
are due to contaminated PF even though based on the 
time period elapsed from transplantation to the occur-
rence of the infection and the antibiotic sensitivity, it 
is likely that the bacteria responsible of the infections 
are not the same isolated in the PF; thirdly the dura-
tion of the prophylactic antibiotic therapy used in our 
centre at the time of the study was longer compared to 
the accepted general practice and it could reduced the 
sensitivity of the urine culture.
Waiting for largest and prospective clinical trials to 
confirm our findings, the message emerging from this 
study is that although contamination of PF occurs fre-
quently due to a variety of factors including handling of 
the kidney during procurement process, the rate of the 
PF-related infections is negligible. In addition, our data 
suggest that a reduction of the use of preemptive therapy, 
mandatory in the case of fungi isolation, could be consid-
ered in recipients with positive PF for bacteria reducing 
the deleterious impact of antibiotic-resistant organisms 
and saving money. However, we highly recommend a 
closely clinical and microbiologic monitoring of the 
recipient in case of PF contamination in order to estab-
lish a diagnosis as soon as possible and, consequently, 
promptly start the appropriate antibiotic therapy.
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